Biomarker Landscape in RASopathies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 29

PMID 39201250

Authors

Noemi Ferrito

Juan Baez-Flores

Mario Rodriguez-Martin

Julian Sastre-Rodriguez

Alessio Coppola

Maria Isidoro-Garcia

Pablo Prieto-Matos

Jesus Lacal

Affiliations

Soon will be listed here.

Abstract

RASopathies are a group of related genetic disorders caused by mutations in genes within the RAS/MAPK signaling pathway. This pathway is crucial for cell division, growth, and differentiation, and its disruption can lead to a variety of developmental and health issues. RASopathies present diverse clinical features and pose significant diagnostic and therapeutic challenges. Studying the landscape of biomarkers in RASopathies has the potential to improve both clinical practices and the understanding of these disorders. This review provides an overview of recent discoveries in RASopathy molecular profiling, which extend beyond traditional gene mutation analysis. mRNAs, non-coding RNAs, protein expression patterns, and post-translational modifications characteristic of RASopathy patients within pivotal signaling pathways such as the RAS/MAPK, PI3K/AKT/mTOR, and Rho/ROCK/LIMK2/cofilin pathways are summarized. Additionally, the field of metabolomics holds potential for uncovering metabolic signatures associated with specific RASopathies, which are crucial for developing precision medicine. Beyond molecular markers, we also examine the role of histological characteristics and non-invasive physiological assessments in identifying potential biomarkers, as they provide evidence of the disease's effects on various systems. Here, we synthesize key findings and illuminate promising avenues for future research in RASopathy biomarker discovery, underscoring rigorous validation and clinical translation.

References

Beauclair G, Bridier-Nahmias A, Zagury J, Saib A, Zamborlini A . JASSA: a comprehensive tool for prediction of SUMOylation sites and SIMs. Bioinformatics. 2015; 31(21):3483-91. DOI: 10.1093/bioinformatics/btv403. View

Magaki S, Hojat S, Wei B, So A, Yong W . An Introduction to the Performance of Immunohistochemistry. Methods Mol Biol. 2018; 1897:289-298. PMC: 6749998. DOI: 10.1007/978-1-4939-8935-5_25. View

Machado Almeida P, Lago Solis B, Stickley L, Feidler A, Nagoshi E . Neurofibromin 1 in mushroom body neurons mediates circadian wake drive through activating cAMP-PKA signaling. Nat Commun. 2021; 12(1):5758. PMC: 8486785. DOI: 10.1038/s41467-021-26031-2. View

Baez-Flores J, Rodriguez-Martin M, Lacal J . The therapeutic potential of neurofibromin signaling pathways and binding partners. Commun Biol. 2023; 6(1):436. PMC: 10119308. DOI: 10.1038/s42003-023-04815-0. View

Helfferich J, Nijmeijer R, Brouwer O, Boon M, Fock A, Hoving E . Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol. 2016; 104:30-41. DOI: 10.1016/j.critrevonc.2016.05.008. View

Yoshino H, Yin G, Kawaguchi R, Popov K, Temple B, Sasaki M . Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS One. 2019; 14(8):e0219436. PMC: 6685615. DOI: 10.1371/journal.pone.0219436. View

Brems H, Pasmant E, van Minkelen R, Wimmer K, Upadhyaya M, Legius E . Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat. 2012; 33(11):1538-46. DOI: 10.1002/humu.22152. View

Imada E, Strianese D, Edward D, Althaqib R, Price A, Arnold A . RNA-sequencing highlights differential regulated pathways involved in cell cycle and inflammation in orbitofacial neurofibromas. Brain Pathol. 2021; 32(1):e13007. PMC: 8713532. DOI: 10.1111/bpa.13007. View

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M . The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15(1):23. PMC: 5480189. DOI: 10.1186/s12964-017-0177-y. View

10.

Sun L, Xie Y, Wang S, Zhang Z . Cardiovascular Abnormalities and Gene Mutations in Children With Noonan Syndrome. Front Genet. 2022; 13:915129. PMC: 9234298. DOI: 10.3389/fgene.2022.915129. View

11.

Drenckhahn J, Nicin L, Akhouaji S, Kruck S, Blank A, Schanzer A . Cardiomyocyte hyperplasia and immaturity but not hypertrophy are characteristic features of patients with RASopathies. J Mol Cell Cardiol. 2023; 178:22-35. DOI: 10.1016/j.yjmcc.2023.03.003. View

12.

Miot H, Criado P, Silva de Castro C, Ianhez M, Talhari C, Muller Ramos P . JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023; 98(5):656-677. PMC: 10404561. DOI: 10.1016/j.abd.2023.03.001. View

13.

Choi B, Philips M, Chen Y, Lu L, Dai W . K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion. J Biol Chem. 2018; 293(45):17574-17581. PMC: 6231119. DOI: 10.1074/jbc.RA118.003723. View

14.

Nicholson C, Flanagan S, Murati M, Boull C, McGough E, Ameduri R . Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise. Pediatr Dermatol. 2022; 39(2):316-319. DOI: 10.1111/pde.14912. View

15.

Meyerholz D, Ofori-Amanfo G, Leidinger M, Adam Goeken J, Khanna R, Sieren J . Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem. 2017; 65(10):607-618. PMC: 5624366. DOI: 10.1369/0022155417729357. View

16.

Martins A, Jansen A, Rodrigues L, Matos C, Souza M, de Souza J . Lower fasting blood glucose in neurofibromatosis type 1. Endocr Connect. 2015; 5(1):28-33. PMC: 4703950. DOI: 10.1530/EC-15-0102. View

17.

Leoni C, Paradiso F, Foschi N, Tedesco M, Pierconti F, Silvaroli S . Prevalence of bladder cancer in Costello syndrome: New insights to drive clinical decision-making. Clin Genet. 2022; 101(4):454-458. DOI: 10.1111/cge.14111. View

18.

Biayna J, Mazuelas H, Gel B, Terribas E, Dumbovic G, Rosas I . Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation. Sci Rep. 2021; 11(1):3661. PMC: 7878752. DOI: 10.1038/s41598-021-83152-w. View

19.

Fahrner J, Frazier A, Bachir S, Walsh M, Applegate C, Thompson R . A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1. Am J Med Genet A. 2012; 158A(6):1414-21. PMC: 5101836. DOI: 10.1002/ajmg.a.35363. View

20.

Mulero-Navarro S, Sevilla A, Roman A, Lee D, DSouza S, Pardo S . Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia. Cell Rep. 2015; 13(3):504-515. PMC: 4618050. DOI: 10.1016/j.celrep.2015.09.019. View